Overview

A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The study was carried out as a randomised, single-blind, active-controlled, multi-centric, phase III study with two parallel treatment groups. The primary efficacy criterion was the frequency of effective gut cleansing in each of the two treatment groups (grade A or B "overall quality of gut cleansing" as judged by a blinded expert panel on the basis of videotapes recorded during the endoscopic procedure).
Phase:
Phase 3
Details
Lead Sponsor:
Norgine
Treatments:
Ascorbic Acid
Polyethylene glycol 3350